Protein biomarkers for amyotrophic lateral sclerosis

References

• Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet369, 2031–2041 (2007).
   PubMed Web of Science ®Google Scholar
• Baek WS, Desai NP. ALS: pitfalls in the diagnosis. Pract. Neurol.7, 74–81 (2007).
   PubMedGoogle Scholar
• Schymick JC, Talbot K, Traynor BJ. Genetics of sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet.16, 233–242 (2007).
   PubMed Web of Science ®Google Scholar
• Majoor-Krakauer D, Willems PJ, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet.63, 83–101 (2003).
   PubMed Web of Science ®Google Scholar
• Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am. J. Hum. Genet.75, 933–947 (2004).
   PubMed Web of Science ®Google Scholar
• Valentine JS, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem.74, 563–593 (2005).
   PubMed Web of Science ®Google Scholar
• Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert Rev. Mol. Diagn.6, 387–398 (2006).
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx1, 273–283 (2004).
   PubMedGoogle Scholar
• Ince P, Stout N, Shaw P et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol.19, 291–299 (1993).
   PubMed Web of Science ®Google Scholar
• Alexianu ME, Ho BK, Mohamed AH et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol.36, 846–858 (1994).
   PubMed Web of Science ®Google Scholar
• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N. Engl. J. Med.344, 1688–1700 (2001).
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science314, 130–133 (2006).
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Bigio EH, Ince PG et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol.61, 427–434 (2007).
   PubMed Web of Science ®Google Scholar
• Neumann M, Kwong LK, Sampathu DM et al. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol.64, 1389–1394 (2007).
   Google Scholar
• Nystrom T. Role of oxidative carbonylation in protein quality control and senescence. EMBO J.24, 1311–1317 (2005).
   PubMed Web of Science ®Google Scholar
• Gruzman A, Wood WL, Alpert E et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA104, 12524–12529 (2007).
   PubMed Web of Science ®Google Scholar
• Rakhit R, Robertson J, Vande Velde C et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nature Med.13, 754–759 (2007).
   PubMed Web of Science ®Google Scholar
• Sunderland T, Gur RE, Arnold SE. The use of biomarkers in the elderly: current and future challenges. Biol. Psychiatry58, 272–276 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Clark CM et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discovery6, 295–303 (2007).
   PubMed Web of Science ®Google Scholar
• Gil J, Preux P-M, Alioum A et al. Disease progression and survivial in ALS: first multi-state model approach. Amyotroph. Lateral Scler.8, 224–229 (2007).
   PubMed Web of Science ®Google Scholar
• O’toole O, Traynor BJ, Brennan P et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J. Neurol. Neurosurg. Psychiatry79, 30–32 (2008).
   PubMed Web of Science ®Google Scholar
• Kolarcik C, Bowser R. Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease. Mol. Diagn. Ther.10, 281–292 (2006).
   PubMedGoogle Scholar
• Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx1, 189–195 (2004).
   PubMedGoogle Scholar
• Ranganathan S, Nicoll GC, Henry S et al. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph. Lateral Scler.3, 1–7 (2007).
   Google Scholar
• Leigh PN, Simmons A, Williams S et al. Imaging: MRS/MRI/PET/SPECT: summary. Amyotroph. Lateral Scler. Other Motor Neuron. Disord.3(Suppl. 1), S75–S80 (2002).
   PubMed Web of Science ®Google Scholar
• Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics6, 6326–6353 (2006).
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci.7, 41–53 (2006).
   PubMed Web of Science ®Google Scholar
• Adachi J, Kumar C, Zhang Y et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol.7, R80 (2006).
   PubMed Web of Science ®Google Scholar
• West-Nielsen M, Hogdall EV, Marchiori E et al. Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem.77, 5114–5123 (2005).
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Polshyna A, Nicholl G et al. Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling. Clin. Proteom.2, 91–101 (2006).
   PubMedGoogle Scholar
• Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal. Chim. Acta382, 669–678 (2005).
   Google Scholar
• Anderson K, Potter A, Baban D et al. Protein expression changes in spinal muscular atrophy revealed with a novel antibody array technology. Brain126, 2052–2064 (2003).
   PubMedGoogle Scholar
• Connor JR, Mitchell RM, Lee SY et al. Biomarkers in ALS patients stratified by HFE genotype. Soc. Neurosci. Abstr. (2007).
   Google Scholar
• McDonald WH, Yates JR III. Shotgun proteomics and biomarker discovery. Dis. Markers18, 99–105 (2002).
   PubMed Web of Science ®Google Scholar
• Ramstrom M, Ivonin I, Johansson A et al. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography–Fourier transform ion cyclotron resonance mass spectrometry. Proteomics4, 4010–4018 (2004).
   PubMed Web of Science ®Google Scholar
• Comuzzi B, Sadar MD. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cellscience3, 61–81 (2006).
   PubMedGoogle Scholar
• Wong JW, Sullivan MJ, Cagney G. Computational methods for the comparative quantification of proteins in label-free LCn-MS experiments. Brief. Bioinform. (2007).
   PubMedGoogle Scholar
• Elahi E, Kumm J, Ronaghi M. Global genetic analysis. J. Biochem. Mol. Biol.37, 11–27 (2004).
   PubMedGoogle Scholar
• van Es MA, van Vaught PW Blauw HM et al.ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol.6, 869–877 (2007).
   PubMed Web of Science ®Google Scholar
• Schymick JC, Scholz SW, Fung HC et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol.6, 322–328 (2007).
   PubMed Web of Science ®Google Scholar
• Kasperaviciute D, Weale ME, Shianna KV et al. Large-scale pathways-based association study in amyotrophic lateral sclerosis. Brain130, 2292–2301 (2007).
   PubMed Web of Science ®Google Scholar
• Dunckley T, Huentelman MJ, Craig DW et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N. Engl. J. Med.357, 775–788 (2007).
   PubMed Web of Science ®Google Scholar
• van Es MA, van Vught PW, Blauw HM et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat. Genet.40, 29–31 (2008).
   PubMed Web of Science ®Google Scholar
• Bilic E, Bilic E, Rudan I et al. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur. J. Neurol.13, 1340–1345 (2006).
   PubMed Web of Science ®Google Scholar
• Hosback S, Hardiman O, Nolan CM et al. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm. IGF Res.17, 472–479 (2007).
   PubMed Web of Science ®Google Scholar
• Johansson A, Larsson A, Nygren I et al. Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis. Neuroreport14, 1867–1869 (2003).
   PubMedGoogle Scholar
• Ilzecka J, Stelmasiak Z. Brain-derived neurotrophic factor is not altered in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol. Sci.22, 473–474 (2002).
   PubMedGoogle Scholar
• Brettschneider J, Widl K, Schattauer D et al. Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neurosci. Lett.416, 257–260 (2007).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Widl K, Ehrenreich H et al. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neurosci. Lett.404, 347–351 (2006).
   PubMedGoogle Scholar
• Cronin S, Greenway MJ, Ennis S et al. Elevated serum angiogenin levels in ALS. Neurology67, 1833–1836 (2006).
   PubMed Web of Science ®Google Scholar
• Nygren I, Larsson A, Johansson A et al. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport13, 2199–2201 (2002).
   PubMed Web of Science ®Google Scholar
• Devos D, Moreau C, Lassalle P et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology62, 2127–2129 (2004).
   PubMed Web of Science ®Google Scholar
• Moreau C, Devos D, Brunaud-Danel V et al. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J. Neurol. Neurosurg. Psychiatry77, 255–257 (2006).
   PubMed Web of Science ®Google Scholar
• Ilzecka J. Decreased serum endoglin level in patients with amyotrophic lateral sclerosis: a preliminary report. Scand. J. Clin. Lab. Invest.12, 1–5 (2007).
   Google Scholar
• Smirnova IV, Festoff BW. Alterations in serum thrombospondin in patients with amyotrophic lateral sclerosis. J. Neurol. Sci.127, 207–213 (1994).
   PubMedGoogle Scholar
• Ilzecka J, Stelmasiak Z, Dobosz B. Interleukin-1β converting enzyme/caspase-1 (ICE/caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurol. Scand.103, 255–258 (2001).
   PubMedGoogle Scholar
• Poloni M, Facchetti D, Mai R et al. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett.287, 211–214 (2000).
   PubMed Web of Science ®Google Scholar
• Rentzos M, Nikolaou C, Rombos A et al. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron. Disord.8, 283–287 (2007).
   PubMed Web of Science ®Google Scholar
• Rentzos M, Michalopoulou M, Nikolaou C et al. Serum levels of soluble intercellular adhesion molecule-1 (s-ICAM-1) and soluble endothelial leukocyte adhesion molecule-1(s-ELAM-1) in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron. Disord.6, 118–121 (2005).
   PubMedGoogle Scholar
• Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand.114, 205–209 (2006).
   PubMed Web of Science ®Google Scholar
• Wilms H, Sievers J, Dengler R et al. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J. Neuroimmunol.144, 139–142 (2003).
   PubMed Web of Science ®Google Scholar
• Baron P, Bussini S, Cardin V et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve32, 541–544 (2005).
   PubMed Web of Science ®Google Scholar
• Moreau C, Devos D, Brunaud-Danel V et al. Elevated IL-6 and TNF-α levels in patients with ALS: inflammation or hypoxia? Neurology65, 1958–1960 (2005).
   PubMed Web of Science ®Google Scholar
• Ono S, Hu J, Shimizu N et al. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J. Neurol. Sci.187, 27–34 (2001).
   PubMed Web of Science ®Google Scholar
• Houi K, Kobayashi T, Kato S et al. Increased plasma TGF-β1 in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand.106, 299–301 (2002).
   PubMed Web of Science ®Google Scholar
• Ilzecka J, Stelmasiak Z, Dobosz B. Transforming growth factor-β 1 (TGF-β 1) in patients with amyotrophic lateral sclerosis. Cytokine20, 239–243 (2002).
   PubMed Web of Science ®Google Scholar
• Sussmuth SD, Tumani H, Ecker D et al. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 β in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett.353, 57–60 (2003).
   PubMed Web of Science ®Google Scholar
• Beuche W, Yushchenko M, Mader M et al. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport11, 3419–3422 (2000).
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Shimizu N et al. Decreased plasma levels of fibronectin in amyotrophic lateral sclerosis. Acta Neurol. Scand.101, 391–394 (2000).
   PubMed Web of Science ®Google Scholar
• Houi K, Kobayashi T, Kato S et al. Serum type IV collagen increases with duration of amyotrophic lateral sclerosis. Muscle Nerve23, 430–432 (2000).
   PubMedGoogle Scholar
• Otto M, Bahn E, Wiltfang J et al. Decrease of S100 β protein in serum of patients with amyotrophic lateral sclerosis. Neurosci. Lett.240, 171–173 (1998).
   PubMed Web of Science ®Google Scholar
• Ihara Y, Mori A, Hayabara T et al. Superoxide dismutase and free radicals in sporadic amyotrophic lateral sclerosis: relationship to clinical data. J. Neurol. Sci.134, 51–56 (1995).
   PubMed Web of Science ®Google Scholar
• Grundstrom E, Lindholm D, Johansson A et al. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport11, 1781–1783 (2000).
   PubMed Web of Science ®Google Scholar
• Kuncl RW, Bilak MM, Bilak SR et al. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J. Neurochem.81, 178–184 (2002).
   PubMed Web of Science ®Google Scholar
• Kern MA, Friese M, Grundstrom E et al. Amyotrophic lateral sclerosis: evidence for intact hepatocyte growth factor/MET signalling axis. Cytokine15, 315–319 (2001).
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Kakimoto K, Akatsu H et al. Hepatocyte growth factor in cerebrospinal fluid in neurologic disease. Acta Neurol. Scand.106, 99–103 (2002).
   PubMedGoogle Scholar
• Pirttila T, Vanhatalo S, Turpeinen U et al. Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. Acta Neurol. Scand.109, 337–341 (2004).
   PubMed Web of Science ®Google Scholar
• Ilzecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg.106, 289–293 (2004).
   PubMed Web of Science ®Google Scholar
• Nagata T, Nagano I, Shiote M et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of ALS patients Neurol. Res.29, 772–776 (2007).
   PubMed Web of Science ®Google Scholar
• Nagata T, Nagano I, Shiote M et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of ALS patients Neurol. Res.29, 772–776 (2007).
   PubMed Web of Science ®Google Scholar
• Sekizawa T, Openshaw H, Ohbo K et al. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci.154, 194–199 (1998).
   PubMed Web of Science ®Google Scholar
• Sjogren M, Davidsson P, Wallin A et al. Decreased CSF-β-amyloid 42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord.13, 112–118 (2002).
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand.111, 114–117 (2005).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Sussmuth SD et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology66, 852–856 (2006).
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Jacobsson J, Rosengren L et al. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol.14, 1329–1333 (2007).
   PubMed Web of Science ®Google Scholar
• Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res.987, 25–31 (2003).
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Karlsson JE, Karlsson JO et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem.67, 2013–2018 (1996).
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Williams E, Ganchev P et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem.95, 1461–1471 (2005).
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Ungar LH, Lange DJ et al. Identification of potential CSF biomarkers in ALS. Neurology66, 1218–1222 (2006).
   PubMed Web of Science ®Google Scholar
• Lorenzl S, Albers DS, LeWitt PA et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci.207, 71–76 (2003).
   PubMedGoogle Scholar
• Jacobsson J, Jonsson PA, Andersen PM et al. Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without CuZn-superoxide dismutase mutations. Brain124, 1461–1466 (2001).
   PubMed Web of Science ®Google Scholar
• Ilzecka J. Decreased cerebrospinal fluid cytochrome c levels in patients with amyotrophic lateral sclerosis. Scand. J. Clin. Lab. Invest.67, 264–269 (2007).
   PubMed Web of Science ®Google Scholar
• Matsuishi T, Nagamitsu S, Shoji H et al. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. Short communication. Neural. Transm.106, 943–948 (1999).
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Doppler V, Beucler I et al. APOE: a potential marker of disease progression in ALS. Neurology58, 1112–1114 (2002).
   PubMed Web of Science ®Google Scholar
• Borroni B, Premi E, Di Luca M et al. Combined biomarkers for early Alzheimer disease diagnosis. Curr. Med. Chem.14, 1171–1178 (2007).
   PubMedGoogle Scholar
• Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nature Med.13, 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang YM, Yamamoto M, Kobayashi Y et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol.57, 236–251 (2005).
   PubMed Web of Science ®Google Scholar
• Malaspina A, Kaushik N, de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem.77, 132–145 (2001).
   PubMed Web of Science ®Google Scholar
• Wang XS, Simmons Z, Liu W et al. Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph. Lateral Scler.7, 201–210 (2006).
   PubMed Web of Science ®Google Scholar
• Dangond F, Hwang D, Camelo S et al. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol. Genomics16, 229–239 (2004).
   PubMed Web of Science ®Google Scholar
• Kay A, Petzold A, Kerr M et al. Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome. Stroke34, 637–642 (2003).
   PubMed Web of Science ®Google Scholar
• Russman AN, Lederman RJ, Calabrese LH et al. Multifocal varicella–zoster virus vasculopathy without rash. Arch. Neurol.60, 1607–1609 (2003).
   PubMedGoogle Scholar
• Gruener N, Gozlan O, Goldstein T et al. Iron, transferrin, and ferritin in cerebrospinal fluid of children. Clin. Chem.37, 263–265 (1991).
   PubMedGoogle Scholar
• Lejon V, Robays J, N’Siesi FX et al. Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness. Clin. Vaccine Immunol.14, 732–737 (2007).
   PubMedGoogle Scholar